Highbridge Capital Management’s Celldex Therapeutics CLDX Stock Holding History

Highbridge Capital Management’s Portfolio CLDX Stock Details CLDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q1	–	Sell	-1,347	Closed	-$369K	–	1406
2014 Q4	$369K	Sell	1,347 -7,993	-86%	-$1.99M	﹤0.01%	904
2014 Q3	$1.82M	Buy	9,340 +2,460	+36%	+$536K	0.02%	509
2014 Q2	$1.68M	Buy	+6,880	New	+$1.55M	0.02%	449
2014 Q1	–	Sell	-940	Closed	-$342K	–	1067
2013 Q4	$342K	Buy	+940	New	+$362K	﹤0.01%	790
2013 Q3	–	Sell	-1,120	Closed	-$262K	–	1289
2013 Q2	$262K	Buy	+1,120	New	+$221K	﹤0.01%	1088

Other funds holding CLDX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

CWAM

Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return

KLP Enterprises Branford, Connecticut $1.97M AUM

Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Highbridge Capital Management's CLDX Position: Q2 2017 in Review

Highbridge Capital Management sold out of Celldex Therapeutics (CLDX) in Q2 2017, closing a stake of 10,474 shares — an estimated $567K sold.

Highbridge Capital Management first reported a position in CLDX in Q2 2013 and held it in 8 quarters. The position peaked at $963K in Q1 2014. 130 funds tracked by Wall St. Rank hold CLDX as of Q2 2017.

Highbridge Capital Management reported no remaining Celldex Therapeutics position as of Q2 2017 after selling out during the quarter.
Highbridge Capital Management sold 10,474 Celldex Therapeutics shares in Q2 2017, an estimated $567K.
Highbridge Capital Management first reported a position in Celldex Therapeutics in Q2 2013 and held it in 8 quarters.
Highbridge Capital Management's Celldex Therapeutics position peaked at $963K in Q1 2014.
130 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2017.

Based on Highbridge Capital Management's 13F filing for Q2 2017, filed 14 Aug 2017.